Evaxion Biotech (EVAX) has released an update.
Evaxion Biotech reported promising results from a Phase 2 clinical trial of their AI-designed cancer vaccine, EVX-01, at the ASCO Annual Meeting 2024. The vaccine, which targets neoantigens in melanoma, has shown to elicit specific immune responses without severe adverse effects. These findings validate the effectiveness of Evaxion’s AI-Immunology platform and offer hope for developing personalized cancer treatments.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
